Jeff Franco

Jeffrey Franco is the Chief Executive Officer of OcuDyne, Inc., a clinical-stage ophthalmology company focused on novel perfusion-based approaches to geographic atrophy and other retinal diseases. Under his leadership, OcuDyne announced encouraging 6-month results showing visual-function improvements and increased choroidal thickness in GA patients.
Prior to OcuDyne, Franco led product strategy and business development efforts in ophthalmic innovation, bridging medical research with emerging therapeutic platforms around ocular perfusion and ischemic influence in retinal disease. His record reflects both technology translation and early-stage enterprise building.
Franco holds a strong interest in the intersection of vascular biology and vision, and he actively engages with investor- and innovation-driven forums in the eye-care sector. He frequently speaks at meetings on the future of retina and platform therapeutics.